Litcius/Paper detail

Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26)

G. Créhange, Che Mabubu M’vondo, Aurélie Bertaut, Renata Junqueira Pereira, E. Rio, D. Peiffert, K. Gnep, Karen Bénézery, Philippe Ronchin, G. Noël, Laurent Mineur, Antoine Drouillard, Julie Blanc, Magali Rouffiac, Jihane Boustani

2021International Journal of Radiation Oncology*Biology*Physics44 citationsDOI

Topics & Concepts

MedicineEsophageal cancerRadiation therapyChemoradiotherapyClinical endpointRandomizationConcomitantPopulationRandomized controlled trialStage (stratigraphy)Dose fractionationCancerSurgeryInternal medicinePaleontologyEnvironmental healthBiologyEsophageal Cancer Research and TreatmentGastric Cancer Management and OutcomesLung Cancer Diagnosis and Treatment
Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26) | Litcius